| Literature DB >> 23282077 |
Lingyao Zeng1, Jian Yu, Tao Huang, Huliang Jia, Qiongzhu Dong, Fei He, Weilan Yuan, Lunxiu Qin, Yixue Li, Lu Xie.
Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most fatal cancers in the world, and metastasis is a significant cause to the high mortality in patients with HCC. However, the molecular mechanism behind HCC metastasis is not fully understood. Study of regulatory networks may help investigate HCC metastasis in the way of systems biology profiling.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23282077 PMCID: PMC3535701 DOI: 10.1186/1471-2164-13-S8-S14
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Schematic overview of constructing combinatorial networks and analyzing differential regulatory modules. (A). Construction of combinatorial networks. (B). Analyses based on constructed networks.
Overall statistics about the nodes and edges of the HCC non-metastatic and metastatic networks
| Non-metastatic | Metastatic | |
|---|---|---|
| #TF | 135 | 176 |
| #miRNA | 20 | 63 |
| #gene | 1070 | 1516 |
| #TF-TF | 111 | 124 |
| #TF-miRNA | 2 | 5 |
| #TF-gene | 1350 | 1761 |
| #miRNA-TF | 4 | 21 |
| #miRNA-gene | 43 | 193 |
Figure 2Comparison of global regulatory patterns between the HCC non-metastatic and metastatic networks. (A)(B). Comparison of node- and edge- distributions between the HCC metastatic and non-metastatic networks. Nodes or edges were divided into three categories: only in non-metastatic network(NM-specific), only in metastatic network(M-specific), and common in both networks. (C). Increased rate of average number of targets of a regulator in the metastatic network versus the non-metastatic. For each TF- or miRNA- relations as a whole, average number of targets was calculated in each network, and then the increased rate of the average number of targets in the metastatic network versus the non-metastatic one was represented in barplot. The color of the bar represents the type of targets, TF in green, miRNA in red, and gene in blue.
Figure 3Performance of the 17-module classifier. (A). Classification performance of accumulated modules. The x axis represents the number of "genes" involved in the modules, including TFs, miRNAs, or genes, and the y axis represents the value of prediction accuracy(ACC) and Matthew correlation coefficient(MCC). Performance of classifiers whose number of "genes" within 300 are showed. One dot on a line represents addition of one more module. When the number of modules accumulated to 17, ACC overrides 90% and MCC overrides 80%. (B). Survival difference of the predicted non-metastatic and metastatic groups by the 17-module classifier. Kaplan-Meier estimation was calculated to plot the survival curve. Log-rank test was used to compare two survival distributions and generate the p value.
Full list of 17 regulatory modules predictive of HCC metastasis.
| Module name | Regulator | Targets |
|---|---|---|
| hsa_miR_326_M | hsa-miR-326 | ARHGDIA, CEP250, MYO6, TYR, PWP2, RCBTB2, POLR3F |
| hsa_miR_323_3p_M | hsa-miR-323-3p | BCLAF1, SUMO1, TMBIM6, FAM168B |
| hsa_miR_16_M | hsa-miR-16 | NFATC3, ETNK1, BMX, NCOR2, POLR3F |
| hsa_let_7e_M | hsa-let-7e | CLP1, NGF |
| FOXO3_M | FOXO3 | MICAL1, SAMD8, FUBP3, ATXN10, ADAM11, RAB5C, MRPS24, DPAGT1, GPS1, SNRPC, SUMO1, TWF1, SAR1A, PICALM, TXNDC5, HEXIM2, TRIP12, ZDHHC15, SEMA4G, EFHD2 |
| hsa_miR_22_M | hsa-miR-22 | SLC6A1, SLC35A4 |
| hsa_miR_326_NM | hsa-miR-326 | MTERFD2, ARHGDIA, PCSK4, CEP250, PTRF, MYO6, ST6GALNAC6 |
| hsa_miR_204_M | hsa-miR-204 | CHD5, ATF2, POU2F2, TOMM70A, WDR26, SPOP, FAM168B, PLAA, WASF2, SRXN1 |
| POU2F2_M | POU2F2 | SPIB, C20ORF43, SUCNR1, PTRF |
| NFYB_M | NFYB | NTN4, CACNG5, C12ORF10, TUBA1B, CALB2, RGMA, APOC3, PGD, NDUFV1, CHDH, FBXO24, TCTN2 |
| hsa_miR_30a_M | hsa-miR-30a | CREB1, PAWR, NEDD4, RRAS2, VPS26B, TBC1D2B, HTR4, ACAP2, ZFAND5, SPAG9, MICAL1, ATG5 |
| hsa_miR_7_M | hsa-miR-7 | PDCD2, POLR2E, NF2, FAM168B, MEGF9 |
| CUX1_NM | CUX1 | RUNX1, IFITM2, MARCH5, GPR21, RPL35, TNFRSF10B, CFP, SDHAF2, NUP62CL, YARS, NAGK, GRAMD1A, PLXNB2, BCL2L13, METTL11A, MARK3, ITM2A, HIP1R, BSG |
| FOXO3_NM | FOXO3 | MAFF, LEPROT, MICAL1, PSME1, SAMD8, FUBP3, ATXN10 |
| STAT1_NM | STAT1 | MYBL1, MAFF, POLA1, EXOG, PGM1, ZDHHC4, WDR24, AMFR, RAD52, TMEM208, MRPL34, GCHFR, ANKRD30A, TRO, LDHAL6A, SERPING1, RNASE4, ARPC5L, SRSF3, CD248 |
| TP53_NM | TP53 | ANKRD52, SLC25A20, PGM1, C1QTNF4, PKDCC |
| STAT1_M | STAT1 | WDR24, RAD52, GCHFR |
NM indicates the existence of the module in non-metastatic HCC gene regulatory network, M indicates the existence of the module in metastatic HCC gene regulatory network.
Enriched KEGG non-metabolic pathways of the 17 key regulatory modules.
| Module name | KEGG pathway | P value |
|---|---|---|
| FOXO3_NM | 03050~Proteasome | 0.0342 |
| 05213~Endometrial cancer | 0.0213 | |
| 05223~Non-small cell lung cancer | 0.0221 | |
| TP53_NM | 04110~Cell cycle | 0.039 |
| 04115~p53 signaling pathway | 0.0212 | |
| 04210~Apoptosis | 0.027 | |
| 04310~Wnt signaling pathway | 0.0459 | |
| 04722~Neurotrophin signaling pathway | 0.0384 | |
| 05014~Amyotrophic lateral sclerosis (ALS) | 0.0163 | |
| 05210~Colorectal cancer | 0.0191 | |
| 05212~Pancreatic cancer | 0.0215 | |
| 05213~Endometrial cancer | 0.016 | |
| 05214~Glioma | 0.02 | |
| 05215~Prostate cancer | 0.0273 | |
| 05216~Thyroid cancer | 0.009 | |
| 05217~Basal cell carcinoma | 0.0169 | |
| 05218~Melanoma | 0.0218 | |
| 05219~Bladder cancer | 0.013 | |
| 05220~Chronic myeloid leukemia | 0.0224 | |
| 05222~Small cell lung cancer | 0.0258 | |
| 05223~Non-small cell lung cancer | 0.0166 | |
| hsa_miR_16_M | 04330~Notch signaling pathway | 0.024 |
| 04370~VEGF signaling pathway | 0.0386 | |
| 04662~B cell receptor signaling pathway | 0.0381 | |
| hsa_let_7e_M | 04210~Apoptosis | 0.0181 |
| 04722~Neurotrophin signaling pathway | 0.0258 | |
| hsa_miR_30a_M | 04140~Regulation of autophagy | 0.0425 |
| 04144~Endocytosis | 0.0264 | |
| STAT1_M | 03440~Homologous recombination | 0.0086 |
| 04062~Chemokine signaling pathway | 0.0385 | |
| 04620~Toll-like receptor signaling pathway | 0.0209 | |
| 04630~Jak-STAT signaling pathway | 0.0317 | |
| 05212~Pancreatic cancer | 0.0144 |
One-sided Fisher's Exact Test was used to test whether the genes in a module were significantly enriched in any KEGG non-metabolic pathways. Six modules (FOXO3_NM, TP53_NM, hsa_miR_16_M, hsa_miR_30a_M, hsa_let_7e_M, STAT1_M) of which the resultant p values less than 0.05 are included in this table.
Figure 4Differential regulatory network and key miRNA regulators of HCC metastasis. (A). Differential regulatory network of the 17 classifying modules and their enriched pathways. The green edges represent edges whose CLR weights are larger in network of non-metastasis, while the orange ones represent edges whose weights are larger in network of metastasis. The color and shape of the nodes represent the type of "genes": TF in green rectangle, miRNA in red triangle, and gene in blue eclipse. Six regulators of which modules were enriched in KEGG non-metabolic pathways are highlighted in nodes with larger size and yellow border (hsa-miR-16, hsa-miR-30a, hsa-let-7e, STAT1, TP53, FOXO3). The graph structure of KEGG pathways embodied by gene(protein)-gene(protein) interactions was retrieved by the R package KEGGgraph. (B). Differential regulatory network of miR-30a. (C). Differential regulatory network of miR-16. (D). Differential regulatory network of let-7e/miR-204.
Comparison of clinical characteristics between predicted subgroups of venous metastasis
| Predicted NM | Predicted M | P value | |
|---|---|---|---|
| Patient cohort (n = 198) | n = 137 | n = 61 | |
| Gender(male/female) | 121/16 | 53/8 | 0.9601 |
| Age(yr, mean ± SD) | 49.99 ± 11.22 | 50.15 ± 9.54 | 0.8235 |
| Number of nodule(1/2/3/4) | 117/18/2 | 55/4/1/1 | 0.2603 |
| Tumor capsule(complete/none) | 53/84 | 24/37 | 0.9441 |
| Cirrhosis(no/yes) | 8/129 | 5/56 | 0.7584 |
| AFP(log2-transformed, mean ± SD) | 6.79 ± 3.96 | 8.08 ± 4.56 | |
| TB(μmol/L, median(25-75%)) | 15.4(12.1-20.2) | 17.4(11.4-22.1) | 0.2954 |
| ALT(μ/L, median(25-75%)) | 43(31-61) | 49(32-66) | 0.3929 |
| OKUDA stage(0/1) | 119/18 | 49/12 | 0.3325 |
| CLIP stage(0/1/2/3/4) | 64/49/22/1/1 | 28/15/12/4/2 | 0.0509 |
| BCLC stage(0/A/B/C) | 15/103/14/5 | 7/35/7/12 | |
| TNM stage(I/II/III) | 65/57/15 | 23/23/15 | |
| Child-Pugh class(A/B) | 132/5 | 57/4 | 0.5910 |
P value: Comparison between clinic pathological indicators of non-metastatic and metastatic groups was conducted using chi-square test for discrete variables and Wilcoxon test for continuous variables.
Figure 5Association network of key regulatory modules to clinical pathological characteristics. The association between each key regulatory module and clinical pathologic characteristics was examined using an R/Bioconductor package GlobalAncova. Yellow diamonds represent clinical characteristics and purple octagons represent regulatory modules. An edge connects a module and a clinical parameter if the p value resulted from the GlobalAncova test is significant (p < 0.05). Module hsa_let_7e_M did not have association with any clinical features, so it is not shown in the figure.